Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Aly

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Prostate Cancer and Prostatic Diseases|September 2, 2018
The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohortAxel Möller, Henrik Olsson, Henrik Grönberg, et al.
European Urology Focus|July 30, 2017
Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 ModelTobias Nordström, Henrik Grönberg, Jan Adolfsson, et al.
European Urology|January 15, 2018
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test PotentialPeter Ström, Tobias Nordström, Markus Aly, et al.
Scandinavian Journal of Urology|December 2, 2015
A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsiesTobias Nordström, Ola Bratt, Joakim Örtegren, et al.
European Urology|October 23, 2012
Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011Tobias Nordström, Markus Aly, Mark S Clements, et al.
European Urology Oncology|August 15, 2019
A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance ImagingThorgerdur Palsdottir, Tobias Nordström, Markus Aly, et al.
European Urology Focus|February 14, 2018
Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort StudyMarkus Aly, Mark Clements, Caroline E Weibull, et al.
BMC Cancer|August 27, 2020
The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trialAndrea Porserud, Patrik Karlsson, Elisabeth Rydwik, et al.
Scandinavian Journal of Urology|December 27, 2019
Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/mlJan Chandra Engel, Thorgerdur Palsdottir, Markus Aly, et al.
JAMA Oncology|May 19, 2022
Association of 5α-Reductase Inhibitors With Prostate Cancer MortalityLars Björnebo, Tobias Nordström, Andrea Discacciati, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Prostate Cancer and Prostatic Diseases|September 2, 2018
The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohortAxel Möller, Henrik Olsson, Henrik Grönberg, et al.
European Urology Focus|July 30, 2017
Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 ModelTobias Nordström, Henrik Grönberg, Jan Adolfsson, et al.
European Urology|January 15, 2018
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test PotentialPeter Ström, Tobias Nordström, Markus Aly, et al.
Scandinavian Journal of Urology|December 2, 2015
A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsiesTobias Nordström, Ola Bratt, Joakim Örtegren, et al.
European Urology|October 23, 2012
Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011Tobias Nordström, Markus Aly, Mark S Clements, et al.
European Urology Oncology|August 15, 2019
A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance ImagingThorgerdur Palsdottir, Tobias Nordström, Markus Aly, et al.
European Urology Focus|February 14, 2018
Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort StudyMarkus Aly, Mark Clements, Caroline E Weibull, et al.
BMC Cancer|August 27, 2020
The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trialAndrea Porserud, Patrik Karlsson, Elisabeth Rydwik, et al.
Scandinavian Journal of Urology|December 27, 2019
Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/mlJan Chandra Engel, Thorgerdur Palsdottir, Markus Aly, et al.
JAMA Oncology|May 19, 2022
Association of 5α-Reductase Inhibitors With Prostate Cancer MortalityLars Björnebo, Tobias Nordström, Andrea Discacciati, et al.
Pageof 9